Noxopharm Limited (ASX:NOX)

Australia · Delayed Price · Currency is AUD

0.0610

-0.0010 (-1.61%)

Oct 8, 2026, 11:23 AM AEST

Market Cap	18.74M -27.1%
Revenue (ttm)	1.43M -49.4%
Net Income	-4.46M
EPS	-0.01
Shares Out	307.24M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,006
Open	0.0610
Previous Close	0.0620
Day's Range	0.0610 - 0.0610
52-Week Range	0.0510 - 0.1100
Beta	0.13
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About Noxopharm

Noxopharm Limited, a clinical-stage biotechnology company, engages in the development of therapies for chronic inflammation, autoimmune diseases, and cancer in the Pan-Pacific region. The company develops Sofra, a platform designed to regulate innate immune signaling with greater precision; and Chroma, a small molecule technology platform focused on the development of multiple drug candidates for cancer treatment. It is also developing SOF-SKN, a topical therapy that has completed Phase I clinical trial for cutaneous lupus erythematosus; and CR... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Country Australia

Stock Exchange Australian Securities Exchange

Ticker Symbol NOX

Full Company Profile

Financial Performance

In fiscal year 2026, Noxopharm's revenue was 1.43 million, a decrease of -49.40% compared to the previous year's 2.82 million. Losses were -4.46 million, -8.77% less than in 2025.

Financial Statements